Special Issue "Osteogenesis Imperfecta—Current and Future Therapies"
Deadline for manuscript submissions: 20 April 2024 | Viewed by 2567
Interests: Bone and Extracellular Matrix Branch; Osteogenesis Imperfecta(OI); Collagen; Skin Fibroblasts; Natural Products
Interests: Genetics, connective tissues, hereditary connective tissue diseases, infectious diseases, periodontium, molecular mechanisms, aetiopathogenesis, virulence, cell therapy, genetic engineering
Special Issues, Collections and Topics in MDPI journals
Osteogenesis Imperfecta (OI) is a group of rare inherited skeletal disorders with a wide spectrum of phenotypes characterized primarily by bone fragility. Bone mineral density may be reduced in OI, but the key mechanism of bone fragility is reduced bone quality due to defects in bone matrix and mineralization. Initially, four types of disease caused by mutations in collagen type I genes, ranging from mild to lethal, were known. The continuous discovery of new mutations in non-collagen genes has resulted in a genotype-based classification system including more than 20 OI types. Despite tremendous progress in understanding the pathogenesis of OI, this has not been accompanied by progress in the treatment, which requires a multidisciplinary approach involving a pediatrician, surgeon, orthopedist, and physiotherapist. The main drugs used in the treatment of children and adults with OI are antiresorptive bisphosphonates. A new antiresorptive drug such as denosumab and bone anabolic agents such as teriparatide and inhibitors of sclerostin or TGF-β are under investigation for the treatment of OI. The main disadvantages of these therapies are relatively poor efficacy, no effect in some patients, or cytotoxic side effects. New directions of therapy with the use of chemical chaperone (4-phenylbutyric acid, 4-PBA) or natural products of plant origin (rosemary extract), aimed at ER stress, are promising.
In this Special Issue, original research and review articles describing the experience of the effectiveness of treatment with the use of currently tested drugs and the development of new therapeutic approaches are highly welcome.
Dr. Anna Galicka
Dr. Katarzyna Gawron
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- osteogenesis imperfecta (OI);
- antiresorptive therapy (bisphosphonates, denosumab);
- bone anabolic agents (teriparatide and inhibitors of sclerostin and TGF-β);
- inductors of autophagy (4-PBA, natural products);
- new approaches for OI treatment